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ABSTRACT
Pneumonia remains the leading cause of childhood
mortality and the most common reason for adult
hospitalisation in low and middle income countries,
despite advances in preventative and management
strategies. In the last decade, pneumonia mortality
in children has fallen to approximately 1.3 million cases
in 2011, with most deaths occurring in low income
countries. Important recent advances include more
widespread implementation of protein-polysaccharide
conjugate vaccines against Haemophilus inﬂuenzae type
B and Streptococcus pneumoniae, implementation of
case-management algorithms and better prevention and
treatment of HIV. Determining the aetiology of
pneumonia is challenging in the absence of reliable
diagnostic tests. High uptake of new bacterial conjugate
vaccines may impact on pneumonia burden, aetiology
and empiric therapy but implementation in immunisation
programmes in many low and middle income countries
remains an obstacle. Widespread implementation of
currently effective preventative and management
strategies for pneumonia remains challenging in many
low and middle income countries.
INTRODUCTION
Pneumonia is a major cause of morbidity and mor-
tality in children and adults in low and middle
income countries (LAMICs). In the last decade
there have been several advances and new interven-
tions, resulting in a substantial reduction in pneu-
monia incidence and improved outcomes. These
include more widespread use of case management
strategies, development and implementation of
polysaccharide-protein conjugate vaccines, better
prevention of HIV transmission and uptake of
effective antiretroviral therapy (ART) of
HIV-infected adults and children. As a result there
has been a considerable reduction in pneumonia
mortality in children under 5 years of age, from 1.7
million cases globally in 2000 to 1.3 million cases
in 2011.1 Nevertheless, pneumonia remains the
major cause of death in children worldwide beyond
the neonatal period; this is especially concerning as
most pneumonia deaths should be preventable.2
Further, pneumonia remains the most common
reason for adult hospitalisation in sub-Saharan
Africa, with an estimated 4 million episodes and
200 000 deaths each year.3
CHILDHOOD PNEUMONIA
Epidemiology and aetiology
In 2011, there were an estimated 120 million epi-
sodes of childhood pneumonia globally, of which
14 million progressed to severe disease, with 1.3
million deaths.1 Most deaths (81%) occurred in
children under 2 years of age.1 The incidence and
severity of childhood pneumonia was highest in
Africa and southeast Asia, which accounted for
30% and 39% respectively of the global burden of
severe cases.1 In these two regions, 15 countries
accounted for two-thirds of all childhood pneumo-
nia episodes and severe cases.1 Estimates of hospi-
talisation for acute lower respiratory tract infection
(ALRI) in children in 2010 provide an indication of
the large burden of disease with almost 12 million
hospitalisations for severe disease and 3 million for
very severe infection.4 Even more concerning is the
estimate that more than 80% of deaths occurred
outside a hospital; 99% of deaths occurred in
LAMICs.
Risk factors for pneumonia and for severe
disease include poor nutrition including micronu-
trient deﬁciency, lack of breastfeeding, exposure to
indoor air pollution or passive smoke exposure,
HIV infection, premature birth, overcrowding and
poor living circumstances.5–8 HIV-infection is a
particularly important risk factor in children in
sub-Saharan Africa where the burden of paediatric
HIV disease is concentrated.7 Children with HIV
infection develop more severe pneumonia, have a
higher mortality and have an increased risk of
pneumonia from opportunistic organisms such as
Pneumocystis jirovecii and cytomegalovirus.7
Identiﬁcation of the aetiology of pneumonia is
challenging as few children develop bacteraemic
illness and high prevalence of nasopharyngeal col-
onisation by potentially pathogenic bacteria, limits
the use of respiratory samples for diagnosing bac-
terial pneumonia. Nevertheless data from
vaccine-probe studies indicate that the predominant
aetiologic agent is Streptococcus pneumoniae,
which is estimated to cause 18% of severe cases
and 33% of deaths.1 9 Other important vaccine
preventable pathogens include Haemophilus inﬂu-
enzae type b (Hib), estimated to account for 4% of
severe episodes and 16% of deaths and inﬂuenza
virus which is associated with approximately 7% of
severe episodes and 11% of deaths.1 With
improved vaccine uptake, the importance of the
vaccine-targeted pathogens is anticipated to dimin-
ish,9 while a greater proportion of cases may occur
due to Staphylococcus aureus, Klebsiella pneumo-
niae and Mycobacterium tuberculosis in tubercu-
losis (TB) endemic areas.
Other respiratory viruses, other than inﬂuenza
virus, also contribute considerably to the burden of
childhood pneumonia. Globally, an estimated 100
million cases of viral-associated pneumonia occur
annually in children; respiratory syncytial virus
(RSV), rhinovirus, human metapneumovirus,
human bocavirus, and parainﬂuenza viruses are the
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most common viral pathogens identiﬁed in afﬂuent and in
LAMICs.9 10 In 2005, RSV was estimated to cause approxi-
mately 34 million episodes of ALRI in children under 5 years or
22% of all ALRI; 10% of episodes resulted in severe illness and
hospitalisation and 99% of deaths occurred in LAMICs.11 With
improved immunisation against the main bacterial pathogens,
respiratory viruses may become more prominent as aetiologic
agents of pneumonia. Moreover, current evidence suggests
severe pneumonia results from infection with multiple patho-
gens such as bacterial-viral, dual viral or mycobacterial-bacterial
infections.9 10 Up to a third of children with pneumonia may
have viral-bacterial co-infections.10
Treatment
The cornerstone of effective treatment for childhood pneumo-
nia remains appropriate antibiotics and supportive care includ-
ing oxygen.2 12 Use of oxygen systems in children with hypoxic
pneumonia can reduce mortality by approximately 20%.13 Use
of the pneumonia case management strategy included in the
World Health Organisation Integrated Management of
Childhood Illness (IMCI) programme has consistently been
reported to reduce childhood mortality by approximately 20%,
with even higher reductions in pneumonia speciﬁc mortality.14
Community based case management of childhood pneumonia
may reduce pneumonia mortality by 70%.15 Accumulating evi-
dence suggests that community based use of oral antibiotics for
severe pneumonia may be a feasible and effective strategy for
reducing mortality.12 16 17 Furthermore, short course antibiotic
therapy (3 rather than 5 days) has been reported to be effective
for pneumonia in immunocompetent children.18
The reduction of Hib and pneumococcal associated pneumo-
nia through use of conjugate (HibCV and PCV) immunisation,
underscores the need to reconsider the empiric treatment of
pneumonia in settings where there are strong national immun-
isation programmes. With high coverage of HibCV, Hib is
unlikely to contribute to a sizeable portion of pneumonia. The
relative ongoing role of pneumococcus as an aetiologic agent
for pneumonia, however, remains to be fully elucidated and
may vary depending on the prevalence of disease causing non-
vaccines serotypes. The impact of PCV and HibCV on the aeti-
ology of childhood pneumonia in LAMICs is currently being
evaluated in a large multicentre study, the Pneumonia Etiology
Research for Child Health (PERCH) study.6
Prevention in the era of conjugate vaccines
Improved access to health care, better nutrition, promotion of
breast feeding, improved living conditions and reduced exposure
to indoor pollutants may contribute to the reduction in inci-
dence of pneumonia and decline in case fatality rates.2 6 8 In
areas of south east Asia and Latin America, high exposure to
biomass fuel remains an important factor impacting on the inci-
dence and severity of childhood pneumonia, while in many
LAMICs passive exposure to cigarette smoke is highly preva-
lent.8 Improved home ventilation and reduction in exposure to
indoor air pollution and cigarette smoke are important strategies
to reduce the severity and incidence of childhood pneumonia.
For HIV-infected children, use of ART early in the course of
HIV infection and of cotrimoxazole prophylaxis can substan-
tially reduce the burden of pneumonia and of severe disease.7
Prevention of pneumonia has also been expedited by the
introduction of HibCV and PCV.2 Combined data from six
studies of the effectiveness of HibCV in LAMICs indicates a
reduction of 18% in radiological pneumonia, of 6% in severe
pneumonia and of 7% in pneumonia-associated mortality.2
Progress toward the inclusion of HibCV into public immunisa-
tion programmes lagged behind in low income countries, with
HibCV introduced in <25% of low-income countries by 2006,
almost 20 years since its licensure in developed countries.19
More recently, through support from Global Alliance for
Vaccines and Immunisation (GAVI), approximately 90% of low-
income countries had introduced HibCV in 2011.19
A conservative estimate of the role of pneumococcus in child-
hood pneumonia has also been possible through vaccine-probe
studies. Overall, data from six studies in LAMICs estimated a
reduction of 29% in radiologically conﬁrmed pneumonia, of 11%
in severe pneumonia and of 18% in pneumonia-speciﬁc mortality.2
Notably, the prevention of non-bacteraemic pneumococcal pneu-
monia was 20-fold greater compared to that of vaccine-serotype
bacteraemic pneumonia.20 21 The reduction in radiologic-
conﬁrmed pneumonia from PCV is mainly due to reductions in
vaccine-serotype disease and occasionally some cross-reactive sero-
types. Consequently, the use of PCVas a vaccine-probe may under-
estimate the overall contribution of pneumococcus as an aetiologic
agent for radiologic-conﬁrmed pneumonia.
Data from the PCV9 study among HIV-uninfected South
African children reported vaccine efﬁcacy against vaccine-
serotype invasive disease (IPD) of 83% and 35% against all
serotype IPD, with a 20% reduction in radiologic-conﬁrmed
pneumonia.21 Based on the assumption that the serotypes
causing pneumonia are similar to those causing IPD, it is likely
that PCV9 only prevented one-third of non-bacteraemic
pneumococcal pneumonia; therefore a signiﬁcant proportion
(possible up to two-thirds) of the residual burden of radiologic-
conﬁrmed pneumonia among PCV-vaccinated children may still
be due to pneumococcus either due to incomplete protection
against vaccine-serotype pneumonia, or due to lack of efﬁcacy
against non-vaccine serotypes. Despite these draw-backs, PCV
has resulted in a dramatic decline in all-cause pneumonia hospi-
talisation in several countries, especially in children less than
2 years of age. This included a 56% reduction following
7-valent PCV introduction in a middle-income country such as
Uruguay,22 as well as a sustained reduction (43% decrease) in
children under 2 years in USA,23 10-years following PCV intro-
duction. The reduction of pneumonia in USA among children
2–4 years of age has, however, been more modest (12%).23
Furthermore, widespread PCV immunisation of infants has also
led to a dramatic decline in the rates of hospitalisation for pneu-
monia in adults, especially the elderly.23 24 PCV has also been
associated with reduction in hospitalisation for viral-associated
pneumonia. A post hoc analysis of the South African PCV9
study found a 32% lower hospitalisation rate for pneumonia
episodes associated with respiratory viruses in vaccinated chil-
dren.25 Effectiveness studies in countries with widespread PCV
immunisation have corroborated these ﬁndings for example, a
41–50% reduction in inﬂuenza virus attributable pneumonia
hospitalisation for every 10% increment in childhood PCV
immunisation in the USA.24 A case-control study in Spain
reported a 48% reduction for inﬂuenza hospitalisation asso-
ciated with the H1N1 pandemic in PCV fully-vaccinated chil-
dren during 2009–2010, however, a similar protective effect
against seasonal-inﬂuenza virus hospitalisation in 2010–2011
was not found.26 Furthermore, PCV vaccination of infants has
also provided insight into the role of pneumococcus in precipi-
tating hospitalisation for acute severe pneumonia in children
with underlying TB in TB endemic settings. Another post hoc
analysis of the South African PCV9 trial indicated that 43% of
hospitalisation in children with culture-conﬁrmed TB was due
to a pneumococcal co-infection.27
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Progress has also been made in developing vaccines which are
more immunogenic and efﬁcacious against inﬂuenza virus.
These include the live attenuated inﬂuenza vaccine (LAIV) and
MF-59 adjuvanted inactivated inﬂuenza vaccines, both of which
have a higher relative efﬁcacy compared to non-adjuvanted inac-
tivated inﬂuenza vaccine (IIV) against inﬂuenza conﬁrmed
illness. Among children age 12–24 months old, the relative efﬁ-
cacy of LAIV was 55% compared to IIV,28 and in children 6–
72 months of age adjuvanted IIV had a 75% higher relative efﬁ-
cacy in preventing inﬂuenza conﬁrmed illness compared to
IIV.29
ADULT PNEUMONIA
Epidemiology
Pneumonia is the most common cause of infectious disease
related death among adults worldwide and is associated with
age, HIV infection and smoking. In LAMICs, where life expect-
ancy is much lower than in developed economies, the dominant
risk factors are HIV and smoke exposure.
The association of pneumonia and HIV infection is CD4
dependent with exponential increases in incidence with decreasing
CD4.30 ART roll-out in many resource poor settings has reduced
the incidence of pneumonia among HIV infected adults but anti-
pneumococcal immunity is not fully restored by ART.31 32 It is
therefore unsurprising that in HIV endemic areas, pneumonia
remains the most common cause of inpatient admission as many
people are only diagnosed as HIV infected at presentation with
pneumonia and progression to AIDS remains common.33
Pneumonia outcomes among HIV infected people have been
reported as similar to HIV uninfected patients given optimal
therapy but patients with HIV often present with complex
co-infections and co-morbidity.34
Smoke exposure in developed countries is predominantly
tobacco related but in LAMICs there is an equal burden of
disease attributed to household air pollution. The association of
upper and lower respiratory tract infection with biomass fuel
exposure has been known for some time35 but there are no data
to conﬁrm that an intervention to reduce smoke exposure can
reduce adult pneumonia. Intense efforts to reduce biomass fuel
consumption and household air pollution have been driven by
political will to reduce environmental destruction, ameliorate
climate change and empower women—the evidence to support
a health effect, and the data with which to choose appropriate
technology are urgently needed.
Aetiology of adult pneumonia in resource poor settings
Whilst S pneumoniae is a universally common cause of adult
pneumonia globally, there are marked regional differences in the
frequencies of other pathogens that are important to consider
when selecting empirical antimicrobial treatment or determining
the need for additional microbiological investigations. In many
low-resource settings, there is a particularly high incidence of
pulmonary TB. In Kenya, for example, M tuberculosis was the
second most commonly identiﬁed pathogen in a large prospect-
ive cohort study of adults with pneumonia and notably symp-
toms of 14 days or less.36 In China and several other Asian
countries, high rates of pneumonia attributable to atypical bac-
terial pathogens, particularly Mycoplasma pneumoniae, are
commonly reported and macrolide resistance is a growing
problem.37 38 K pneumoniae has emerged as a frequent cause of
severe pneumonia in both Asia and South Africa and substantial
rates of multi-drug resistance have been observed.39 40
Burkholderia pseudomallei, the causative agent of melioidosis, is
endemic throughout much of South-East Asia and frequently
presents as an acute severe pneumonic illness. In some rural
areas, it is the most commonly identiﬁed cause of severe pneu-
monia.41 The emergence of several novel respiratory viral infec-
tions from LAMICs in recent years serves to highlight the
importance of continued vigilance to novel pathogens in
patients presenting with acute pneumonia.
Pathogen speciﬁc diagnostic tests in adult pneumonia
In developed settings, treatment algorithms based on aetiology
have failed to show a therapeutic beneﬁt and this has driven clin-
ical apathy towards precise microbiological diagnosis.42 In settings
where HIV infection is found in most adults presenting with pneu-
monia, however, it is probable that pathogen directed care, at least
to distinguish bacterial infection from TB or P jirovecii pneumonia,
will provide substantial beneﬁt. In the setting of severe disease,
accurate positive or negative results would be extremely useful in
ruling treatment options in or out. This need for diagnostic preci-
sion and regionally relevant management strategy is the currently
the subject of focused cohort studies.
The role of respiratory viruses in both HIV infected and unin-
fected adults in resource poor settings is unknown and is the
subject of intense current research effort. Surveillance studies, led
by Centers for Disease Control and Prevention (CDC), USA and
clinical outcome prospective cohorts are in progress. The inter-
action of inﬂuenza and bacterial infection discussed above with
regard to child vaccination is likely to also pertain in adults.43 It
is unlikely, however, that current viral or bacterial diagnostic tests
would alter therapy even in resource poor settings.
MANAGEMENT, TREATMENT AND ANTIBIOTIC REGIMENS
IN ADULT PNEUMONIA
Severity scores
Appropriate initial management of pneumonia relies on an
accurate assessment of disease severity. To support clinical
assessment, which is poorly predictive of disease outcome,
several severity-scoring indices have been developed. These
tools facilitate the prompt identiﬁcation of individuals with
severe disease, permitting the rapid institution of intensive care
interventions. Equally, they help treating physicians to conﬁ-
dently identify individuals with low-severity disease who may be
safely managed at home. Care provided in accordance with
treatment guidelines based on an assessment of disease severity
using a severity-scoring index is associated with improved
outcome.44 Nonetheless, many severity assessment tools may
actually underestimate disease severity in young people.45 This
is of particular relevance in LAMICs where a greater burden of
pneumonia is seen in younger adults.36 Similarly, differences in
population comorbidity burden and aetiological spectrum of
pneumonia may reduce the prognostic performance of most
pneumonia severity assessment tools that were almost exclu-
sively developed and validated in well-resourced settings. There
is an urgent need for the development of validated severity
assessment tools in LAMICs that can support clinical manage-
ment decisions in these settings.
TREATMENT
In the absence of data from high quality randomised controlled
trials, the optimal antimicrobial treatment for moderate or high
severity community-acquired pneumonia remains uncertain.
Observational studies support the use of combination antimicro-
bial therapy with a β-lactam and macrolide.46 The beneﬁcial
effect of inclusion of macrolide antibiotics are not limited to
pneumonia caused by atypical bacteria, but are also evident in
severe pneumococcal pneumonia and disease due to
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macrolide-resistant pathogens,47 suggesting that non-
antimicrobial effects of macrolides may be relevant. The
growing interest in the putative immunomodulatory properties
of macrolide antibiotics in the treatment of pneumonia is tem-
pered by concerns over their cardiovascular safety proﬁle.48 The
role of adjunctive immunomodulatory therapies in the treatment
of pneumonia more generally remains undeﬁned. Prospective
studies of corticosteroids have yielded variable and inconclusive
results.49 The need for improved therapies remains pressing
given the lack of substantial advancement in outcomes of severe
pneumonia in the last decades.
Notwithstanding this, recent studies have demonstrated that
there are still substantial gains to be made in improved treatment
outcomes in pneumonia by the implementation of simple best
practice, particularly rapid measurement and correction of
hypoxia, and prompt provision of appropriate antibiotics and
intravenous ﬂuids.50 This care-bundle approach has been suc-
cessfully used to improve outcomes in severe sepsis and the par-
allels to the treatment of pneumonia are clear. In resource poor
settings, however, basic resuscitation is often difﬁcult and in par-
ticular, oxygen provision is minimal.51 Despite these challenges,
this approach presents an important therapeutic opportunity
that is the focus of current research.
Indiscriminate use of broad spectrum antibiotics has been
appreciated as a major cause of developed country hospital mor-
bidity due to Clostridium difﬁcile.52 This burden of iatrogenic
disease has largely been avoided in low resource settings owing
to the more parsimonious use of antibiotics in general and
broad spectrum antibiotics in particular. The future spectre of
increased antibiotic resistance in settings with limited ability to
purchase sophisticated new drugs is a current worry, however, as
is the relative paucity of antibiotics in development.
In well-resourced settings, there is a growing body of evidence
demonstrating a continuing excess mortality that persists for
many months after surviving an episode of pneumonia.53
Increased rates of cardiovascular events have been implicated as
the predominant explanation with coronary artery plaque desta-
bilisation related to the intense systemic response during pneu-
monia representing a plausible biological mechanism.54
Strategies to mitigate this risk with the use of aspirin and HMG
CoA reductase inhibitors are the focus of current interest. As
the burden of coronary-artery disease increases in LAMICs,
these long-term health implications of pneumonia may become
more apparent.
Prevention of pneumonia in adults
Globally, vaccination of adults is poor. This is particularly the
case in resource-poor settings but, fortunately, there is a substan-
tial impact to be gained in prevention of adult disease from the
vaccination of children. This has been dramatically demon-
strated in the USA with PCV but also shown to be region and
vaccine-speciﬁc with the UK experience showing less herd
immunity.55 56 Vaccination of HIV infected adults to prevent
invasive pneumococcal disease was a success using conjugate
vaccine but failed using polysaccharide vaccine.57 58 This para-
doxical result where a T cell dependent vaccine was successful
even in severely immunocompromised adults has not been fol-
lowed by widespread adoption of vaccination of HIV infected
adults. Current research is focused on the timing of post-ART
vaccination and on the herd protection effects achievable with
polyvalent conjugate vaccination of children in communities
with high HIV seroprevalence. Pneumococcal vaccination in the
context of inﬂuenza pandemic will have a role but this has not
yet been deﬁned, nor has the need for inﬂuenza vaccination in
HIV infected people.
CONCLUSIONS
Pneumonia continues to present a major burden of morbidity
and mortality in resource poor regions despite advances in pre-
ventative and management strategies. There is an urgent need
for improved diagnostics to reliably identify aetiological agents.
More widespread implementation and scale up of immunisation
with improved conjugate vaccines against childhood pneumonia
in LAMICs could substantially reduce childhood mortality and
the burden of pneumonia. Implementation of current effective
preventative and management strategies remains a challenge in
many LAMICs although the available interventions can substan-
tially reduce pneumonia burden, severity and outcome.
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